Selcia Limited has launched a new platform that enables drug discovery and development on the target family of peptidyl-prolyl cis-trans isomerases (PPIases).
The scope of the service includes drug screening, functional assays, compound profiling as well as determining specificity of inhibition against a representative panel of enzymes.
Selcia has already started the delivery of clinical PPIase inhibitors to pharma clients, which have important therapeutic potential in the area of infections, inflammation, neuroprotection and cancer.
Selcia has also developed assays for members of all PPIase families and is expanding the set of enzymes available for screening and profiling.
The primary function of PPIases is to catalyse the cis-trans isomerisation of the X-Pro peptide bonds in polypeptide chains.
Selcia discovery business development director Simon Bury said PPIases are a large and unexploited family of drugable targets, which are not amenable to HTS.
''Selcia is the only company offering this PPIase screening service and has the capability to take a PPIase target from hit finding to candidate stage,'' Bury added.
''Selcia's unique panel of PPIase screening assays was developed by our biology team to enable screening of compounds designed and synthesised by our medicinal chemists for several integrated drug discovery programs.''
